Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06621251 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
A Phase 2 study of Prosthetic Joint Infections of Hip and Prosthetic Joint Infections of Knee, sponsored by Trellis Bioscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 17
- Study locations
NCT06621251 is a Phase 2 study of Prosthetic Joint Infections of Hip and Prosthetic Joint Infections of Knee that is actively recruiting participants, run by Trellis Bioscience. The registered enrollment target is 60 participants. The trial reports 17 study locations across 10 states.
The verdict
NCT06621251, a Phase 2 study of Prosthetic Joint Infections of Hip and Prosthetic Joint Infections of Knee, is actively recruiting participants, sponsored by Trellis Bioscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 17
- Study locations
Study Summary
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.
Conditions Studied
Interventions
- DRUG TRL1068 (calpurbatug), a human monoclonal antibody
- PROCEDURE DAIR
Study Locations (17)
Texas
- Proactive RGV - Brownsville
- University of Texas Medical Branch at Galveston - Galveston
- Houston Methodist - Houston
- Paradigm Research Center - Houston
- North Texas Medical Research Institute - Rockwall
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Gulfcoast Research Institute - Sarasota
- Phoenix Clinical Research - Tamarac
New York
- NYU Langone Health - New York
- University of Rochester - Rochester
Arizona
- OrthoArizona - Gilbert
Arkansas
- University of Arkansas for Medical Sciences (UAMS) - Little Rock
California
- UCLA - Los Angeles
Maryland
- Sinai Hospital Baltimore - Baltimore
Massachusetts
- New England Baptist Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06621251
The ClinicalTrials.gov registry entry for NCT06621251 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trellis Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prosthetic Joint Infections of Hip appearing as the primary indexed condition, and to 2 interventions - of which TRL1068 (calpurbatug), a human monoclonal antibody is the first listed.
NCT06621251 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Texas, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06621251 about?
NCT06621251 is a clinical study titled "Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection". TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination w...
What is the current status of trial NCT06621251?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-04-08. Estimated completion is 2026-11.
What conditions does trial NCT06621251 study?
This clinical trial studies the following conditions: Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee.
What interventions are being tested in trial NCT06621251?
The interventions under investigation include: TRL1068 (calpurbatug), a human monoclonal antibody (DRUG), DAIR (PROCEDURE).
Who is sponsoring clinical trial NCT06621251?
This trial is sponsored by Trellis Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06621251 being conducted?
This trial has 17 study locations across Arizona, Arkansas, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Prosthetic Joint Infections of Hip
All registered trials for this condition
Prosthetic Joint Infections of Knee
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.